Polarean Imaging plc
01/27/2023 | Press release | Archived content
Block Listing Six Monthly Return
Corporate News
Block Listing Six Monthly Return
27 January 2023
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Polarean Imaging Plc | ||||
| Name of scheme: | Polarean Share Option Plan | ||||
| Number and class of securities originally admitted: | 8,000,000 ordinary shares of £0.00037 each | ||||
| Date of admission: | 29 July 2021 | ||||
| Period of return: | From: | 28 July 2022 | To: | 26 January 2023 | |
| Balance of unallotted securities under scheme(s) from previous return: | 4,025,657 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | ||||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
0 |
||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 4,025,657 | ||||
| Total number of securities in issue at the end of the period | 213,047,509 | ||||
| Name of contact: | Richard Hullihen, Chief Executive Officer |
| Telephone number of contact: |
Tel: +44 (0)20 7933 8780 or [email protected] |
Enquiries:
| Polarean Imaging plc | https://www.polarean.com / https://www.polarean-ir.com | ||||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | ||||
| Kenneth West, Chairman | |||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) | |||||
| Nick Adams / Nick Harland (Corporate Broking) | |||||
| Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
||||
| Anna Dunphy /Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 | ||||
About Polarean (https://www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean's vision is to help address the global unmet medical needs of patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized). 129Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.
XENOVIEWTM is a trademark of Polarean, Inc. POL-PR-2201
« back to Corporate News
Latest News
-
Holding(s) in Company
11 September 2025 -
Submission of new Phase III study protocol to FDA for expanded indication of XENOVIEW
12 August 2025 -
Block Listing Six Monthly Return
24 July 2025
Corporate News
View About us
About Us
Share Price
Share Price
-
GBp
-
-
-
Annual Report & Account 2024 (inc. Notice of AGM)
Latest Annual Report
Important Dates
Important dates
09 Jun
Annual General Meeting
08 May
Final Results
Investor Alert
Sign up for Email Alerts
Investor Alert
Polarean Imaging plc published this content on January 27, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 10:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]